[ Price : $8.95]
FDA and AstraZeneca reach agreement on label changes for Faslodex injection that updates results from the companys CONFIRM trial i...[ Price : $8.95]
An FDA report discusses the 35 new molecular entities the agency approved in FY 2012.[ Price : $8.95]
Lawyers from Skadden and Foley Hoag examine the future of FDA and Justice Department enforcement actions in the wake of this weeks...[ Price : $8.95]
FDA and Peregrine Pharmaceuticals reach agreement on the design of a single registration drug trial for Cotara in patients with re...[ Price : $8.95]
FDA Webview editor Jim Dickinson analyzes FDAs loss of a potent off-label drug marketing case, calling it a staggering strategic b...[ Price : $8.95]
FDA approves a Mylan Pharmaceuticals ANDA for candesartan cilexetil and hydrochlorothiazide tablets, a generic copy of AstraZeneca...[ Price : $8.95]
Former FDA inspector Patrick Stone says the agency should adhere to internal timelines for completing inspections and issuing Warn...[ Price : $8.95]
FDA considers new surrogate endpoints for clinical trials in chronic kidney disease patients based on a special scientific worksho...